Interviews

In the first article of a 2-part series, Yara Abdou, MD, discussed the most significant challenges and transformative advancements in the treatment of HER2-positive breast cancer.

In an interview with Targeted Oncology, Charu Aggarwal, MD, MPH, discussed the real-world study evaluating the link between molecular genotyping and survival among patients with non–small-cell lung cancer.

In an interview with Targeted Oncology, Jie Jin, MD, discussed the need for a standard therapy in peripheral T-cell lymphoma and highlighted the potential impact of the JACKPOT26 study.

In an interview with Targeted Oncology, Guenther Koehne, MD, provides a comprehensive overview of the dynamic landscape and evolving strategies in immunotherapy for hematologic malignancies.

In an interview with Targeted Oncology, Louise Morrell, MD, discussed the landscape of genetic testing in oncology and the latest advancements in the field.

In an interview with Targeted Oncology, Amer Assal, MD, provided insights into the risks and complications associated with stem cell transplants, emphasizing the importance of risk stratification and preventive measures.

Matthew J. Frigault, MD, MS, discussed follow-up data on the efficacy and safety of CART-ddBCMA for the treatment of patients with relapsed/refractory multiple myeloma, particularly in later-line settings.

In an interview with Targeted Oncology, Jon E. Arnason, MD, discussed an analysis looking at circulating tumor DNA among patients with follicular lymphoma and diffuse large B-cell lymphoma from the ELM-2 trial.

In an interview with Targeted Oncology, Naomi Dempsey, MD, provided insight into the benefits of endocrine therapy in patients with breast cancer and the implications of findings from this research.

David J. Andorsky, MD, discussed real-world findings from a study which evaluated BTK inhibitors in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In an interview with Targeted Oncology, Jonathan W. Riess, MD, discussed the ever-changing EGFR-mutated lung cancer treatment landscape, highlighting several agents that are currently under development.

In an interview with Targeted Oncology, Lee Greenberger, PhD, discussed some of the latest, interesting research that caught his attention in 2023 and what community oncologists should know about the space as we move into 2024.

Haifa Kathrin Al-Ali, MD, discussed findings from the phase 1/2 CA011-023 study of BMS-986158 combined with ruxolitinib or fedratinib in myelofibrosis.

In an interview with Targeted Oncology, Ann LaCasce, MD, MMSc, delved into the surge of innovations with personalized medicine, advanced technologies, and novel agents for the treatment of patients with lymphomas.

In an interview with Targeted Oncology, Andre Goy, MD, discussed the potential of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory mantle cell lymphoma and how 2 studies provide support for use of the agent in this patient population.

In an interview with Targeted Oncology, Francis P. Worden, MD, shed light on the evolving landscape of advanced thyroid cancer treatment, offering valuable insights into the available options.

In an interview with Targeted Oncology, James Zou, PhD, provided an overview of AI and machine learning applications in oncology.

In an interview with Targeted Oncology, Jennifer A. Woyach, MD, discussed updated results from the phase 1/2 BRUIN study of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma following treatment with a covalent Bruton tyrosine kinase inhibitor.

In an interview with Targeted Oncology, Daniel Baker, PhD candidate at the University of Pennsylvania, discussed the growing role for CAR T-cell therapies outside of the oncology field.

Andrew Srisuwananukorn, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discussed the use of a novel artificial intelligence model that aids in the differentiating between prefibrotic primary myelofibrosis and essential thrombocythemia.

In an interview with Targeted Oncology™, Michelle M. Issac, MD, discussed the goals of both palliative care and oncology care professionals as they support patients with cancer.

In an interview with Targeted Oncology, Igor Astsaturov, MD, PhD, discussed what led to the development of LP-184 and explained how the agent will be evaluated moving forward.

In an interview with Targeted Oncology, Yazmin Odia, MD, discussed the 3rd Annual Miami Cancer Institute Oncology Rehabilitation Symposium, including her discussion on incorporating rehabilitation into the course of treatment for patients with brain cancer.

In an interview with Targeted Oncology, Eirwen M. Miller, MD, discussed the dynamic landscape of ovarian cancer treatment.

In an interview with Targeted Oncology, Ryan Carey, MD, and Rob Lee, PhD, discussed the preclinical research and the potential for lidocaine to kill certain cancer cells.

In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.

In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.

Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.

In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.

In an interview with Targeted Oncology, City of Hope cancer center’s Marwan Fakih, MD, further discussed the findings from this phase 3 trial and future directions for evaluating this combination.